Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, an established treatment for cancer patients, could offer a novel therapeutic approach to decrease levels of inflammation in the atherosclerotic plaques of patients with cardiovascular disease (CVD), reported an abstract¹ study at the International Conference on Nuclear Cardiology and Cardiac CT, May 5 to 8 in Berlin, Germany. "Our results should act as a stimulus for further exploration of radionuclide based interventions in atherosclerosis...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment